Shock wave impact on the viability of MDA-MB-231 cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
12
2019
accepted:
19
05
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Shock waves are gaining interests in biological and medical applications. In this work, we investigated the mechanical characteristics of shock waves that affect cell viability. In vitro testing was conducted using the metastatic breast epithelial cell line MDA-MB-231. Shock waves were generated using a high-power pulse laser. Two different coating materials and different laser energy levels were used to vary the peak pressure, decay time, and the strength of subsequent peaks of the shock waves. Within the testing capability of the current study, it is shown that shock waves with a higher impulse led to lower cell viability, a higher detached cell ratio, and a higher cell death ratio, while shock waves with the same peak pressure could lead to different levels of cell damage. The results also showed that the detached cells had a higher cell death ratio compared to the attached cells. Moreover, a critical shock impulse of 5 Pa·s was found to cause the cell death ratio of the detached cells to exceed 50%. This work has demonstrated that, within the testing range shown here, the impulse, rather than the peak pressure, is the governing shock wave parameter for the damage of MDA-MB-231 breast cancer cells. The result suggests that a lower-pressure shock wave with a longer duration, or multiple sequential low amplitude shock waves can be applied over a duration shorter than the fundamental response period of the cells to achieve the same impact as shock waves with a high peak pressure but a short duration. The finding that cell viability is better correlated with shock impulse rather than peak pressure has potential significant implications on how shock waves should be tailored for cancer treatments, enhanced drug delivery, and diagnostic techniques to maximize efficacy while minimizing potential side effects.
Identifiants
pubmed: 32497154
doi: 10.1371/journal.pone.0234138
pii: PONE-D-19-35577
pmc: PMC7272042
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0234138Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ultrasound Med Biol. 1990;16(6):581-5
pubmed: 2238266
J Transl Med. 2015;13:93
pubmed: 25784614
Ultrasound Med Biol. 1990;16(6):595-605
pubmed: 2238268
Biochim Biophys Acta. 2002 Jan 30;1542(1-3):186-94
pubmed: 11853891
Cancer Res. 1999 Oct 15;59(20):5227-32
pubmed: 10537301
Sci Rep. 2014 Jan 24;4:3849
pubmed: 24458018
Clin Orthop Relat Res. 2001 Jun;(387):8-17
pubmed: 11400898
Soft Matter. 2014 Jul 21;10(27):4778-88
pubmed: 24818846
Cancer Res. 1993 Apr 1;53(7):1590-5
pubmed: 8453628
Clin Vaccine Immunol. 2011 Apr;18(4):539-45
pubmed: 21307276
Ultrasound Med Biol. 1995;21(7):961-7
pubmed: 7491750
Ultrasound Med Biol. 1990;16(7):687-98
pubmed: 2126407
Int J Cancer. 1993 Aug 19;55(1):153-6
pubmed: 8344746
Ultrasound Med Biol. 1993;19(2):137-46
pubmed: 8516960
Ultrasonics. 1993;31(2):75-89
pubmed: 8438532
Neurosurg Focus. 2012 Jan;32(1):E3
pubmed: 22208896
PLoS One. 2012;7(10):e46536
pubmed: 23094027
J Orthop Surg Res. 2012 Mar 20;7:11
pubmed: 22433113
Lab Chip. 2015 Jan 7;15(1):264-73
pubmed: 25361042
Biochim Biophys Acta. 2003 Dec 5;1624(1-3):131-8
pubmed: 14642823
Biophys J. 2000 Oct;79(4):1821-32
pubmed: 11023888
Lab Chip. 2008 Jul;8(7):1034-41
pubmed: 18584076
Int J Hyperthermia. 2015 May;31(3):302-9
pubmed: 25367011
Drug Discov Today. 2014 Apr;19(4):502-9
pubmed: 24486324
J Neurosurg. 2007 Apr;106(4):667-76
pubmed: 17432720